CorMedix, Inc. (CRMD)
| Market Cap | 289.84M |
| Revenue (ttm) | 208,295 |
| Net Income (ttm) | -21.24M |
| Shares Out | 29.60M |
| EPS (ttm) | -0.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 2 |
| Last Price | $7.62 |
| Previous Close | $9.02 |
| Change ($) | -1.40 |
| Change (%) | -15.52% |
| Day's Open | 8.91 |
| Day's Range | 7.60 - 9.18 |
| Day's Volume | 4,099,003 |
| 52-Week Range | 2.16 - 18.80 |
The FDA gave a thumbs-down to CorMedix's antibacterial/anti-fungal catheter lock.
The FDA has issued a Complete Response Letter for CorMedix Inc's (NASDAQ: CRMD) marketing application seeking approval for DefenCath (taurolidine/heparin catheter lock solution) for catheter-r...
BERKELEY HEIGHTS, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prev...
BERKELEY HEIGHTS, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for th...
CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does CorMedix (CRMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
BERKELEY HEIGHTS, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for th...
CorMedix Inc. (CRMD) CEO Khoso Baluch on Q3 2020 Results - Earnings Call Transcript
CorMedix (CRMD) delivered earnings and revenue surprises of 15.38% and 116.28%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
CorMedix's (CRMD) CEO Khoso Baluch On Q3 2020 Results - Quick Version Earnings Call Transcript
Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector Seasoned industry veteran with decades of strategic and commercial leaders...
BERKELEY HEIGHTS, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for th...
BERKELEY HEIGHTS, N.J., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for th...
It may be unusual to see nearly a 10% gain from a single analyst call. When analysts call for upside of more than 100% it can attract some attention.
Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector Seasoned industry veteran with decades of strategic and commercial leaders...
BERKELEY HEIGHTS, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...
BERKELEY HEIGHTS, N.J., Aug. 31, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...
CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
CorMedix's (CRMD) CEO Khoso Baluch on Q2 2020 Results - Earnings Call Transcript
CorMedix (CRMD) delivered earnings and revenue surprises of 41.67% and -83.16%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time
Cormedix (AMEX: CRMD) unveils its next round of earnings this Monday, August 10.
BERKELEY HEIGHTS, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...
BERKELEY HEIGHTS, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD) (the “Company”), a biopharmaceutical company focused on developing and commercializing therapeut...
CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Priority Review of NDA Requested Priority Review of NDA Requested
CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q1 2020 Results - Earnings Call Transcript
CorMedix (CRMD) delivered earnings and revenue surprises of 8.70% and -48.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
BERKELEY HEIGHTS, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...
BERKELEY HEIGHTS, N.J., April 23, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...
Top Ranked Momentum Stocks to Buy for April 22nd
BERKELEY HEIGHTS, N.J., April 22, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...
As of late, it has definitely been a great time to be an investor CorMedix
CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q4 2019 Results - Earnings Call Transcript
CorMedix (CRMD) delivered earnings and revenue surprises of 12.50% and -73.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BERKELEY HEIGHTS, N.J., Feb. 03, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...
BERKELEY HEIGHTS, N.J., Feb. 03, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...
CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q3 2019 Results - Earnings Call Transcript
CorMedix (CRMD) delivered earnings and revenue surprises of 12.00% and -68.42%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...
Pre-NDA Meeting Scheduled Pre-NDA Meeting Scheduled
BERKELEY HEIGHTS, N.J., Sept. 26, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...
BERKELEY HEIGHTS, N.J., Sept. 26, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...
CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q2 2019 Results - Earnings Call Transcript
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About CRMD
CorMedix, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, critical/intensive care, and oncology. The company was... [Read more...]
| Industry Biotechnology | IPO Date Mar 25, 2010 |
| CEO Khoso Baluch | Employees 30 |
| Stock Exchange NASDAQ | Ticker Symbol CRMD |
Financial Performance
In 2019, CorMedix's revenue was $283,266, a decrease of -34.09% compared to the previous year's $429,797. Losses were -$16.43 million, -38.75% less than in 2018.
Analyst Forecasts
According to 2 analysts, the average rating for CorMedix stock is "Buy." The 12-month stock price forecast is 25.60, which is an increase of 235.96% from the latest price.